What is Citius Oncology, Inc.'s operating income?

Citius Oncology, Inc. (CTOR) reported operating income of -$28.61M in Q1 2026.

How has Citius Oncology, Inc.'s operating income changed year-over-year?

Citius Oncology, Inc.'s operating income decreased by 283.0% year-over-year, from -$7.47M to -$28.61M.

What does operating income mean?

Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.

Citius Oncology, Inc. CTOR Operating Income

Operating Income at other companies

Delcath SystemsDCTH

-$1.64M-355%

Iovance Biotherapeutics, Inc.IOVA

-$81.04M+33.1%

Cullinan Therapeutics, Inc.CGEM

-$53.7M+2.4%

ImmunomeIMNM

-$59.33M-32.9%

Arcus BiosciencesRCUS

-$134M-9.8%

ImmunityBio, Inc.IBRX

-$69.79M-8.3%

Other financials

Income statement

See full

Revenue$1.7M—

Gross profit$1.3M—

Net income-$26.6M-244%

EPS (diluted)-$0.27-145%

Balance sheet

See full

Cash & equivalents$2.6M+2,350,466%

Total equity$35.3M-1.0%

Total assets$100.7M+10.1%

Cash flow

See full

Operating cash flow-$3.8M-179%

Valuation

See full

Market cap$60.45M-75.9%

Returns & leverage

See full

Return on equity-119.9%+46.7pp

Current ratio0.5×+0.1×

Where this comes from

Reported directly by Citius Oncology, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.

The official record: Citius Oncology, Inc.’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about Citius Oncology, Inc.'s operating income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Citius Oncology, Inc.'s operating income?: Citius Oncology, Inc. (CTOR) reported operating income of -$28.61M in Q1 2026.
How has Citius Oncology, Inc.'s operating income changed year-over-year?: Citius Oncology, Inc.'s operating income decreased by 283.0% year-over-year, from -$7.47M to -$28.61M.
What does operating income mean?: Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.